INTRODUCTION
non‐Hodgkin lymphoma, neutropenia, infections, NHL, CIN, Myelosuppression
NEUTROPENIA, CHILDHOOD CANCER, INFECTIONS, SOLID TUMORS, ADVERSE EFFECT, CIN, NHL, MYELOSUPPRESSION
Myelosuppression is a common potentially life‐threatening adverse effect (AE) of chemotherapy in childhood cancers.Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) is commonly used for reversing CIN,Pegfilgrastim, a PEGylated form of rhG‐CSF (analog of filgrastim), was approved for use in children to reverse CIN and reduce the incidence of neutropenia‐associated infections.Therefore, this prospective multicenter phase II study aimed to examine the safety and efficacy of PEG‐rhG‐CSF as a primary prophylactic drug for neutropenia in pediatric patients with solid tumors or non‐Hodgkin lymphoma (NHL).